Pardes Biosciences, a biopharma upstart based in Carlsbad, California, has announced that the U.S. Patent and Trademark Office has issued a new patent No. 11,124,497. The patent relates to compounds intended to inhibit the main protease (Mpro) of SARS-CoV-2. “This issued patent is the first from our growing IP portfolio and reflects our commitment to…